



## ► PHARMA POOL

**Bob Chib**  
**Cassie Hogenkamp**  
**ASTELLAS ANNOUNCES KEY LEADERSHIP**  
**APPOINTMENTS**


Bob Chib

Astellas has named Bob Chib and Cassie Hogenkamp to key leadership roles within its corporate development function to advance the strategic capabilities of Astellas' Americas operations and further strengthen the company's focus on patient needs.

Mr. Chib is serving as executive director, corporate strategy, planning and initiative management and delivery. He formerly led Astellas' strategic accounts business unit.

Ms. Hogenkamp continues to serve as executive director, commercial strategy and innovation, where she remains focused on leading commercial strategic activities for the Americas. Previously part of the Astellas Pharma US sales and marketing organization, Ms. Hogenkamp and her team now join corporate development.

**Dr. Avinash Desai**  
**Paul Hawthorne**  
**EISAI MAKES EXECUTIVE APPOINTMENTS**


Dr. Avinash Desai

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., has appointed Avinash Desai, M.D., as VP, Americas oncology medical affairs for the oncology business group (OBG).

In this role, Dr. Desai leads Eisai's oncology medical affairs team by creating and overseeing the medical strategy for the oncology commercial and market access businesses in the Americas. Dr. Desai, who has more than 20 years of experience in the oncology field, joins Eisai from Janssen Pharmaceuticals.

Paul Hawthorne has been named senior VP, U.S. commercial, neurology business group. In this role, Mr. Hawthorne is responsible for leading the U.S. neurology sales and marketing teams in bringing Eisai's neurology portfolio of products to patients. Mr. Hawthorne joins Eisai from Sanofi, where he spent the last 24 years; most recently, he held the position of VP, sales.

## ► BIOTECH POOL

**Dr. Michael Ehlers**  
**Michel Vounatsos**  
**BIOPEN STRENGTHENS EXECUTIVE TEAM**

Biogen has named Michael Ehlers, M.D., Ph.D., as executive VP, research and development. Dr. Ehlers



Dr. Michael Ehlers

is charged with overseeing Biogen's global research, drug discovery, clinical development, and medical affairs functions. Dr. Ehlers joins Biogen from Pfizer, where he served as group senior VP for biotherapeutics R&D and chief scientific officer for the company's neuroscience and pain research unit.

Michel Vounatsos has been named executive VP and chief commercial officer. Mr. Vounatsos oversees the development and execution of Biogen's global commercial strategy.

Mr. Vounatsos comes to Biogen after a 20-year career at Merck, where he most recently served as president, primary care business line and Merck customer centricity.

**Mark Enyedy**  
**IMMUNOGEN APPOINTS PRESIDENT**  
**AND CEO**


Mark Enyedy

ImmunoGen, a biotechnology company developing targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, has appointed Mark Enyedy president and CEO.

Mr. Enyedy brings more than 25 years of combined general management, business development and legal experience in the biotechnology industry. He joins ImmunoGen from Shire plc, where he served as executive VP and head of corporate development, leading the company's strategy, M&A, and corporate planning functions and providing commercial oversight for the company's pre-Phase III portfolio.

**Dr. Paul Resnick**  
**MABVAX THERAPEUTICS HIRES CHIEF**  
**BUSINESS OFFICER**


Dr. Paul Resnick

MabVax Therapeutics Holdings, a clinical-stage oncology drug development company, has named Paul Resnick, M.D., to the newly created position of VP and chief business officer, responsible for corporate development, including engaging with large pharmaceutical and biotechnology companies on potential licensing and collaboration arrangements for its products under development.

He has more than 20 years of industry experience spanning large pharmaceutical and public and private biotechnology companies encompassing corporate development, product development, licensing and collaboration, and most recently serving as senior VP at Juventas Therapeutics.

## ► BIOPHARMA POOL

**Dana Alexander**  
**Dr. Stephen Mascioli**  
**ANIKA APPOINTS CHIEF MEDICAL OFFICER**  
**AND CHIEF OPERATIONS OFFICER**


Dr. Stephen Mascioli

Anika Therapeutics, a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, has named Dana Alexander chief operations officer and Stephen Mascioli,

M.D., to the role of chief medical officer.

Mr. Alexander brings nearly two decades of operational expertise in manufacturing and supply chain management, and he spent the last 14 years in various leadership roles at Genzyme.

Dr. Mascioli, an executive with 25 years of experience, previously held the inaugural CMO position at Terumo Americas Holdings, where he built the company's medical department, provided strategic leadership for regulatory and clinical programs, and managed risk assessment and mitigation analysis on patient safety issues.

**Dr. Karin Jooss**  
**GRITSTONE ONCOLOGY APPOINTS CHIEF**  
**SCIENTIFIC OFFICER**


Dr. Karin Jooss

Gritstone Oncology, a cancer immunotherapy company developing next-generation, personalized cancer therapeutics, has named Karin Jooss, Ph.D., as chief scientific officer. Dr. Jooss joins Gritstone from Pfizer, where she served as head of cancer immunotherapeutics and immunopharmacology for seven years.

## ► AGENCY POOL

**Adam Gelling**  
**GIANT NAMES PRESIDENT**


Adam Gelling

Giant Creative/Strategy, a full-service independent healthcare communications agency, has named Principal and Chief Strategy Officer Adam Gelling, as president. He now leads the account services, strategy, client partnerships, and project management groups for Giant's San Francisco and Philadelphia locations. <sup>PV</sup>



FOR BONUS CONTENT  
USE YOUR QR CODE READER  
OR GO TO  
[bit.ly/PV0616-Pool](http://bit.ly/PV0616-Pool)



## ► BIOTECH POOL

**Dr. Patrick Andre**  
**Dr. Randall Halcomb**  
**Hans Hull**

**PLIANT THERAPEUTICS EXPANDS LEADERSHIP TEAM**

Pliant Therapeutics, a company focused on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases, has made three leadership team appointments. Patrick Andre, Ph.D., has been named VP of biology, Randall Halcomb, Ph.D., has joined as VP of medicinal chemistry, and Hans Hull has joined the company as chief business officer.

**Dr. Gail Brown**  
**ARMO BIOSCIENCES EXPANDS LEADERSHIP TEAM**

ARMO BioSciences, a clinical-stage biotechnology company, has appointed Gail Brown, M.D., to the position of chief medical officer. Dr. Brown is responsible for the clinical development of the company's pipeline of immunotherapies, including the lead product candidate AM0010, several cytokines with therapeutic potential, and an anti-PD-1 monoclonal antibody for the treatment of advanced solid tumors.

Dr. Brown has more than 21 years of clinical research and development experience in designing and conducting Phase I through Phase III international clinical trials. Most recently, Dr. Brown was senior medical director at AbbVie, where she worked on the clinical development of Venclexta (venetoclax) in hematologic malignancies.

**Dr. Norman Greenberg**  
**ATRECA EXPANDS LEADERSHIP**

Atreca, a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, has appointed Norman Greenberg, Ph.D., as chief scientific officer. Dr. Greenberg brings to Atreca more than 25 years of experience conducting pioneering research and advancing innovative cancer immunotherapies in the clinic.

Before joining Atreca, Dr. Greenberg was senior VP of translational research at Checkmate Pharmaceuticals, where he was responsible for advancing novel immuno-oncology combination therapeutics in clinical trials.

**Dr. Matthew Moyle**  
**ANAPTYSBIO APPOINTS CHIEF SCIENTIFIC OFFICER**

AnaptysBio, a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology, has appointed Matthew Moyle, Ph.D., as chief scientific officer. Dr. Moyle is responsible for the discovery and early

development of therapeutic antibodies generated using AnaptysBio's proprietary SHM-XEL platform.

Dr. Moyle joins AnaptysBio with more than 25 years of industry experience in discovery and development of biologic therapeutics. Most recently, Dr. Moyle served as VP of biotherapeutics at Boehringer Ingelheim Pharmaceuticals.

## ► BIOPHARMA POOL

**Dr. Gregory Berk**  
**VERASTEM NAMES CHIEF MEDICAL OFFICER**

Verastem, which is focused on discovering and developing drugs to treat cancer, has appointed Gregory Berk, M.D., as chief medical officer. Dr. Berk is responsible for leading the company's global clinical development strategy and clinical operations. Dr. Berk joins Verastem from Sideris Pharmaceuticals where he served as president and chief medical officer.

**Dr. Michael Boretti**  
**Jeannie Chu**  
**Susan Graf**  
**EPIZYME BROADENS EXECUTIVE LEADERSHIP TEAM**

Epizyme, a clinical-stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, has expanded its executive leadership team with the addition of Michael Boretti, Ph.D., as VP of business development, Jeannie Chu as VP program and portfolio management, and Susan Graf, as chief business officer.

Dr. Boretti is leading new partnering opportunities, as well as ongoing alliances. Before Epizyme, he worked in roles of increasing responsibility at AVEO Oncology from 2008 to March 2016, most recently serving as VP, corporate development and alliance management.

Ms. Chu is responsible for creating structured, cross-functional project teams to oversee the development and commercialization of tazemetostat, as well as development of Epizyme's portfolio of epigenetic products. Before Epizyme, she held roles of increasing responsibility at Biogen, most recently as senior director of program leadership and management.

Ms. Graf is charged with overseeing and directing the implementation of Epizyme's new corporate strategy and leading corporate and business development and alliance management. Ms. Graf was most recently VP, corporate development and strategy for NPS Pharma.

**Dr. John McKew**  
**Dr. David Weiner**  
**LUMOS PHARMA MAKES SENIOR LEADERSHIP APPOINTMENTS**

Lumos Pharma, a clinical-stage biotechnology

company focused on bringing novel therapies to patients with unmet medical needs in severe, rare, and genetic diseases, has named John McKew, Ph.D., as chief scientific officer. Dr. McKew most recently served as VP of research for aTyr Pharma.

David Weiner, M.D., joins Lumos Pharma as chief medical officer to steer development of the company's rare and orphan disease therapeutics. Dr. Weiner comes to Lumos from aTyr Pharma, where he served as chief medical officer.

**Dr. Vincent O'Neill**  
**MIRNA APPOINTS CHIEF MEDICAL OFFICER**

Mirna Therapeutics, a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, has appointed Vincent O'Neill, M.D. Dr. O'Neill, a medical oncologist, joins Mirna from Exosome Diagnostics, where he served as chief medical officer.

**Dr. Tuyen Ong**  
**PTC THERAPEUTICS APPOINTS CHIEF MEDICAL OFFICER**

PTC Therapeutics has promoted Tuyen Ong, M.D., to chief medical officer. Dr. Ong joined PTC in 2014 as the senior VP, head of clinical development and translational research. He will continue to play an important role in the development of Translarna for rare genetic disorders as well as the advancement of our company pipeline.

## ► EMERGING PHARMA POOL

**Dr. David Mauro**  
**CHECKMATE PHARMACEUTICALS APPOINTS CHIEF MEDICAL OFFICER**

Checkmate Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing novel approaches for cancer immunotherapy, has appointed David Mauro, M.D., Ph.D., to the newly created position of chief medical officer.

Dr. Mauro brings to Checkmate more than 15 years of experience in early and late stage oncology drug development, clinical, and translational research, and medical affairs. Previously he served as executive VP and chief medical officer at Advaxis, where he was responsible for the strategy and oversight of the company's clinical programs.

**Dr. David Rodman**  
**NIVALIS THERAPEUTICS APPOINTS CHIEF MEDICAL OFFICER**

Nivalis Therapeutics, a clinical-stage pharmaceutical company focused on treating people with cystic fibrosis, has appointed David Rodman, M.D., as chief medical officer and executive VP of discovery. Dr. Rodman most recently served as chief medical officer and executive VP, research and development at miRagen Therapeutics. <sup>PV</sup>



# RATIONAL COMBINATIONS 360°

JUNE 23-24, 2016

PARK LANE HOTEL, NEW YORK, NY

15%  
OFF

FOR PHARMAVOICE  
READERS WITH  
CODE PVCE15

## Novel Clinical Trial Designs for Immuno-Oncology Combinations

### LEAD ADVISOR



Axel Hoos, MD, PhD  
GlaxoSmithKline

### LEAD ADVISOR



Ian McCaffery, PhD  
Corvus Pharmaceuticals

### KEYNOTE SPEAKER



Patrick Hwu, MD  
MD Anderson

### NOVEL TRIAL DESIGNS



Jeffrey Legos, PhD  
Novartis Pharmaceuticals

### COMBINATION LANDSCAPE



Roy Baynes, MD, PhD  
Merck Research Labs

### NOVEL COMBINATIONS STRATEGY



Robert Iannone, MD  
AstraZeneca

### REGULATORY PERSPECTIVE



Ellen Sigal, PhD  
Friends of Cancer Research

### T-CELL COMBOS



Laura Johnson, PhD  
Perelman School of Medicine,  
University of Pennsylvania

### BIOMARKERS



Priti Hegde, PhD  
Genentech

### SYNTHETIC LETHALITY



Patricia Marinello, PharmD  
Merck Research Labs

### INVESTING IN IO COMBINATIONS



Mark Simon, MBA  
Torreya Partners

### PARTNERING STRATEGIES



John DeYoung, MBA  
Pfizer

Organized by

THE **conference** FORUM

Follow us on Twitter @ConferenceForum #IOcombos360

[WWW.THECONFERENCEFORUM.ORG](http://WWW.THECONFERENCEFORUM.ORG)